Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 3/20 | 0.38 |
| ▸ | TTK | P33981 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | IKBKE | Q14164 | 4/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30283211 | 1.00 | NSD2 (0.41) | NSD2LRRK2IRAK4ACHETTK | |
| SCHEMBL30319984 | 0.92 | CTSK (0.42) | NSD2LRRK2IRAK4ACHEALDH1A1 | |
| SCHEMBL24154769 | 0.92 | CTSK (0.42) | NSD2LRRK2IRAK4ACHEALDH1A1 | |
| SCHEMBL25305718 | 0.88 | IRAK4 (0.36) | NSD2LRRK2IRAK4ACHEALDH1A1 | |
| SCHEMBL24154923 | 0.84 | JAK2 (0.38) | IRAK4ACHEALDH1A1MBOAT4CTSK | |
| SCHEMBL24155296 | 0.84 | JAK2 (0.38) | IRAK4ACHEALDH1A1MBOAT4CTSK | |
| SCHEMBL25307503 | 0.84 | JAK2 (0.38) | IRAK4ACHEALDH1A1MBOAT4CTSK | |
| SCHEMBL30283042 | 0.83 | ALDH1A1 (0.39) | IRAK4ACHEALDH1A1MBOAT4CTSK | |
| SCHEMBL30283395 | 0.78 | CHUK (0.42) | IRAK4ACHEALDH1A1MBOAT4 | |
| SCHEMBL30319959 | 0.78 | CHUK (0.42) | IRAK4ACHEALDH1A1MBOAT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400556-A1 | AMIDOPYRIMIDONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-12-05 | — | — | US | disclosed |
| US-20230227449-A1 | AMIDOPYRIMIDONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230227449-A1 | AMIDOPYRIMIDONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230227449-A1 | AMIDOPYRIMIDONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-07-20 | — | — | US | disclosed |
| WO-2021259815-A1 | AMIDOPYRIMIDONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227449-A1 | AMIDOPYRIMIDONE DERIVATIVES | F12, XDH, CYP3A43 | NSD2 2806/4885LRRK2 2116/4885IRAK4 1092/4885 |
| US-20240400556-A1 | AMIDOPYRIMIDONE DERIVATIVES | F12, XDH, CYP3A43 | NSD2 2806/4885LRRK2 2116/4885IRAK4 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.